Assess whether the primary endpoint will survive FDA scrutiny (ecac44)

SITUATION The working file is complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal. CMC change-control owner in a rare-disease team designing a pediatric plan has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; complete-response-letter deficiency list already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the pathway in force until complete-response-letter deficiency list is completed after a DSMB note on an imbalance that is not yet a signal for CMC change-control owner. 3. Treat complete-response-letter deficiency list as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision the primary endpoint will turns on in complete-response-letter deficiency list.

ANALYSIS REQUIRED 1. Check whether complete-response-letter deficiency list supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 3. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, CMC change-control owner must state the unresolved clinical or safety evidence requirement explicitly.